Cargando…

Ready Conversion of Patients with Well-Controlled, Moderate to Severe, Chronic Malignant Tumor–related Pain on Other Opioids to Tapentadol Extended Release

BACKGROUND AND OBJECTIVES: The effectiveness and tolerability of tapentadol extended release (ER), a centrally acting analgesic with μ-opioid receptor agonist and norepinephrine (noradrenaline) reuptake inhibitor activities, have been demonstrated in patients with chronic pain, including those switc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imanaka, Keiichiro, Tominaga, Yushin, Etropolski, Mila, Ohashi, Hiroki, Hirose, Keiichiro, Matsumura, Taka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062813/ https://www.ncbi.nlm.nih.gov/pubmed/24906437 http://dx.doi.org/10.1007/s40261-014-0204-3

Ejemplares similares

Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain
por: Kress, H.G., et al.
Publicado: (2016)

Evaluation of Blood Pressure and Heart Rate in Patients with Hypertension Who Received Tapentadol Extended Release for Chronic Pain: A Post Hoc, Pooled Data Analysis
por: Biondi, David M., et al.
Publicado: (2014)

A Pooled Analysis Evaluating the Efficacy and Tolerability of Tapentadol Extended Release for Chronic, Painful Diabetic Peripheral Neuropathy
por: Schwartz, Sherwyn, et al.
Publicado: (2014)

First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18
por: Finkel, Julia C, et al.
Publicado: (2019)

Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study
por: Sazuka, Shoichiro, et al.
Publicado: (2020)

Tapentadol extended release for the management of chronic neck pain
por: Billeci, Domenico, et al.
Publicado: (2017)

Patient considerations in the use of tapentadol for moderate to severe pain
por: Vadivelu, Nalini, et al.
Publicado: (2013)

Tapentadol extended-release for treatment of chronic pain: a review
por: Vadivelu, Nalini, et al.
Publicado: (2011)

Tapentadol extended release in the management of peripheral diabetic neuropathic pain
por: Vadivelu, Nalini, et al.
Publicado: (2015)

Diversion and Illicit Sale of Extended Release Tapentadol in the United States
por: Dart, Richard C., et al.
Publicado: (2016)

Does ‘Strong Analgesic’ Equal ‘Strong Opioid’? Tapentadol and the Concept of ‘µ-Load’
por: Raffa, Robert B., et al.
Publicado: (2018)

Comparison of the Risks of Shopping Behavior and Opioid Abuse Between Tapentadol and Oxycodone and Association of Shopping Behavior and Opioid Abuse
por: Cepeda, M. Soledad, et al.
Publicado: (2014)

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2018)

A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients
por: Jung, Ji Yoon, et al.
Publicado: (2022)

Tapentadol: an overview of the safety profile
por: Polati, Enrico, et al.
Publicado: (2019)

Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain
por: Samolsky Dekel, Boaz G., et al.
Publicado: (2015)

Tapentadol for the Treatment of Moderate-to-Severe Acute Pain in Children Under the Age of Two Years
por: Eissa, Ayman, et al.
Publicado: (2021)

Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States
por: Cepeda, Maria Soledad, et al.
Publicado: (2010)

Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol
por: Peacock, Amy, et al.
Publicado: (2018)

Multiple effectiveness aspects of tapentadol for moderate–severe cancer-pain treatment: an observational prospective study
por: Cascella, M, et al.
Publicado: (2018)

Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients
por: Muse, Derek, et al.
Publicado: (2019)

Tapentadol hydrochloride: A novel analgesic
por: Singh, Dewan Roshan, et al.
Publicado: (2013)

Outcomes of the Pediatric Development Plan of Tapentadol
por: Eerdekens, Mariëlle, et al.
Publicado: (2021)

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone
por: Haeseler, Gertrud, et al.
Publicado: (2017)

Effectiveness and Tolerability of Tapentadol Prolonged Release Compared With Prior Opioid Therapy for the Management of Severe, Chronic Osteoarthritis Pain
por: Steigerwald, Ilona, et al.
Publicado: (2013)

Tapentadol: an effective option for the treatment of back pain
por: Coluzzi, Flaminia, et al.
Publicado: (2019)

The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy
por: Gonçalves, Leonor, et al.
Publicado: (2015)

A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain?
por: Otto, Jan C., et al.
Publicado: (2019)

Repeated Administration of Clinically Relevant Doses of the Prescription Opioids Tramadol and Tapentadol Causes Lung, Cardiac, and Brain Toxicity in Wistar Rats
por: Barbosa, Joana, et al.
Publicado: (2021)

Prediction of response to tapentadol in chronic low back pain
por: Reimer, M., et al.
Publicado: (2016)

Tapentadol Prolonged Release: A Review in Pain Management
por: Deeks, Emma D.
Publicado: (2018)

Tapentadol: an effective option for the treatment of back pain [Corrigendum]
Publicado: (2019)

Comparison of tapentadol with tramadol for analgesia after cardiac surgery
por: Iyer, Srinivas Kalyanaraman, et al.
Publicado: (2015)

Tapentadol for neuropathic pain: a review of clinical studies
por: Freo, Ulderico, et al.
Publicado: (2019)

Tapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidence
por: Rinonapoli, Giuseppe, et al.
Publicado: (2019)

Tapentadol, the new kid on the block in India: Is it time to worry?
por: Basu, Debasish, et al.
Publicado: (2020)

Trends in dispensing and utilisation of sustained-release tapentadol in Australia.
por: Camacho, Ximena, et al.
Publicado: (2022)

Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease
por: Coluzzi, Flaminia, et al.
Publicado: (2015)

Comparing opioid types in the persistence of opioid use following surgical admission: a study protocol for a retrospective observational linkage study comparing tapentadol and oxycodone in Australia
por: Lam, Tina, et al.
Publicado: (2022)

Comparative Efficacy of Tapentadol versus Tapentadol Plus Duloxetine in Patients with Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Randomized Non-Inferiority Clinical Trial
por: Sansone, Pasquale, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nvveps094ptj2h5gjhcqoenbhh